1. Gianluigi Savarese et al. JCHF 2016;4:870-880
Outcome Analysis in HF Versus No HF Subgroup Risk ratios (RRs) for risk of stroke/embolism; major, total, and intracranial bleeding; and all-cause and cardiovascular death in patients with versus those without heart failure (HF). Solid squares represent RRs in trials and have a size proportional to the number of events. The 95% confidence intervals (CIs) for individual trials are denoted by lines and those for the pooled RRs by diamonds. Event rates are reported as events per patient-years. ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CV = cardiovascular; ENGAGE-AF = Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation; ER = event rate; RE-LY = Randomized Evaluation of Long Term Anticoagulation Therapy; ROCKET-AF = Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trail in Atrial Fibrillation.
Gianluigi Savarese et al. JCHF 2016;4:
American College of Cardiology Foundation